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Abstract
Purpose: To investigate the relationship between renal sinus lipomatosis (RSL) and abdominal visceral and subcuta-
neous fat accumulation and metabolic risk factors.
Material and methods: A total 73 subjects were included in the study. The study group consisted of 35 cases with RSL 
and 38 control cases matched for age and sex. Total, visceral, and subcutaneous abdominal fat areas were measured 
by abdominal computed tomography (CT). The relationship between RSL and visceral abdominal fat, subcutaneous 
abdominal fat, total abdominal fat, high total cholesterol level, high low-density lipoprotein (LDL) cholesterol level, 
high very low-density lipoprotein (VLDL) cholesterol level, high triglyceride level, low high-density lipoprotein 
(HDL) cholesterol level, impaired fasting glucose level, type 2 diabetes mellitus, hypertension (HT), and metabolic 
syndrome (MS) were investigated. 
Results: RSL existence was observed at significantly higher levels statistically in cases with low HDL cholesterol level, 
high LDL cholesterol level, high VLDL cholesterol level, high triglyceride level, high total cholesterol level, and high 
glucose levels. In the presence of MS, DM, and HT, the presence of RSL was at a significantly higher level according 
to the statistics. Logistic regression analysis was performed to examine the factors affecting RSL presence together.  
It was observed that the model formed as the result of the evaluation using the backward method is statistically signif-
icant. Furthermore, the variables of age, high total cholesterol level, high glucose level, and abdominal subcutaneous 
fat were included in the obtained model.
Conclusions: Our study demonstrated an association between the presence of RSL and age, high total cholesterol level, 
high glucose level, and subcutaneous fat.
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Introduction
Renal sinus lipomatosis (RSL) is a benign entity described 
by the excessive accumulation of non-tumourous fatty 
tissue in the kidney sinus [1]. Normally, the kidney sinus 
contains a variable amount of fat that surrounds the up-
per part of the kidney pelvis, renal arteries, renal veins, and 
nerves. In RSL, there is an extreme accumulation of this fat 
but without any encroachment on the normal kidney pa-
renchyma [2]. In general, ultrasonography (USG) findings 
suggest RSL; however, computed tomography (CT) and 
magnetic resonance imaging (MRI) are definitive imaging 
methods to demonstrate RSL. Proliferation of the fatty tis-
sue in the renal sinus can be clearly assessed by CT scan [3].
Metabolic syndrome (MS) includes a number of met-
abolic parameters such as abdominal obesity, hyperten-
sion (HT), insulin resistance/diabetes mellitus, and hyper- 
lipidaemia, which have been demonstrated to be predic-
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tive of cardiovascular diseases [4]. On the other hand, 
abdominal visceral fat is related with MS, and inde-
pendently related to the morbidity and mortality of coro-
nary artery diseases. Therefore, abdominal visceral fat has 
been used as a clinical risk measure for obesity [5].
In the literature, only a few investigations have report-
ed the relationship between renal sinus fat volume and car-
diovascular risk factors, and abdominal visceral fat [6,7]. 
However, no study in the literature has yet looked into the 
relationship between RSL and metabolic risk factors, ab-
dominal visceral fat, and abdominal subcutaneous fat. 
The aim of our study was to investigate the relation-
ship between RSL and metabolic factors, abdominal vis-
ceral fat, and subcutaneous fat.
Material and methods
Among the cases undergoing abdominal CT examina-
tion for the purpose of nonspecific abdominal pain in 
our radiology department, from September 2016 to April 
2017, we retrospectively analysed for the presence of RSL. 
The diagnosis of RSL was made by two experienced ra-
diologists. In all cases of RSL diagnosis, there was an 
extreme accumulation of renal sinus fat but without any 
encroachment on the normal kidney parenchyma, as pre-
viously defined [2]. A total of 73 subjects were included 
in the study. Thirty-five cases with RSL formed the study 
group (Figure 1). Thirty-eight age- and sex-matched cases 
that were observed to have no RSL in abdominal CT ex-
aminations formed the control group. Ethics Committee 
approval was obtained in advance in order to fulfil ethical 
clearance procedures. Patients were excluded from the 
study if they had a severe parenchymal atrophy, chronic 
kidney disease, single kidney, horseshoe kidney, hydrone-
phrosis, calculus in kidney or ureter, malignancy, steroid 
use, high urea and creatinine values in laboratory tests, 
and insufficient medical information. None of the partici-
pants were taking steatogenic drugs.
The data relating to the levels of serum fasting glu-
cose, total cholesterol level, triglyceride level, high-density 
lipo protein (HDL) cholesterol level, low-density lipopro-
tein (LDL) cholesterol level, very low-density lipoprotein 
(VLDL) cholesterol level, the diagnoses of type 2 diabetes 
mellitus (T2 DM) or hypertension (HT), and the use of 
antihypertensive therapy were obtained from the medical 
records of the patients in the study and control groups. 
Hypercholesterolaemia was defined as serum total choles-
terol level > 200 mg/dl. Hypertriglyceridaemia was defined 
as serum triglyceride level ≥ 150 mg/dl. High LDL cho-
lesterol level was defined as serum LDL cholesterol level 
≥ 150 mg/dl, while low HDL cholesterol level was defined 
as serum HDL cholesterol level < 40 mg/dl for men or 
< 50 mg/dl for women. Having a VLDL cholesterol level 
> 40 mg/dl is accepted as reference for high VLDL cho-
lesterol level. Impaired fasting glucose is defined as serum 
fasting glucose level > 100 mg/dl. T2 DM was identified 
based on the diagnoses documented in the medical records 
of the patients, namely by referring to a serum fasting glu-
cose level > 126 mg/dl, or use of insulin or antidiabetic 
drugs. The patients who were detected to use antihyper-
tensive drugs or those with a diagnosis of HT but who were 
not on antihypertensive therapy were considered to be HT 
patients. The diagnosis of MS was made according to the 
National Cholesterol Education Program’s Adult Treatment 
Panel III Report (NCEP-ATPIII) criteria [8] with the ex-
ception of waist circumference, as in the study by Lee et al. 
[8]. Diagnosis of MS required at least two of the following 
criteria; hypertriglyceridaemia, low HDL cholesterol level, 
arterial blood pressure ≥ 130/85 mmHg or treatment for 
hypertension, and fasting blood glucose level ≥ 100 mg/dl.
We performed all abdominal CT examinations with 
a Somatom Sensation 40 multi-detector CT scanner (Sie-
mens Medical Solutions, 2010). We used the following 
parameters for all CT examinations: 125-150 kvP, 150-200 
mAs, 25-30 cm FOV, 1-1.5 pitch range, 3-7 mm collima-
tion. IV contrast-enhanced CT was performed on 38 pa-
tients. All of these patients underwent standard abdomi-
nal CT examination after a standard injection protocol 
(Iopamiro-Ultravist 300 mgl/MI). Injection rate has been 
2-2.5 ml/s. Semi-automated assessment of the subcutaneous 
and the visceral fat compartments were performed through 
a dedicated software package. All abdominal fat measure-
ments were made using the transverse cross-section imag-
es at umbilicus level, as previously described and validated 
[9,10]. The subcutaneous, visceral, and total fat areas were 
derived by software (Figure 2). By this means, the relation-
ship between RSL and abdominal visceral fat, abdominal 
subcutaneous fat, total abdominal fat, high total cholester-
ol level, high LDL cholesterol level, high VLDL cholesterol 
level, high triglyceride level, low HDL cholesterol level, high 
glucose level, T2 DM, HT, and MS were examined.
Figure 1. Computed tomography scan shows proliferation of fat in both 
renal sinuses in a 74-year-old woman
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Results
The ages of the cases ranged between 28 and 89 years, 
with an average of 58.43 ± 15.61 years. 41.7% of the cas-
es (n = 30) were males and 58.3% (n = 42) were females. 
Distribution of the risk factors is shown in Table 1. 
The age, abdominal visceral fat, abdominal subcutaneous 
fat, and total fat were at statistically significantly higher lev-
els in patients with RSL than in the patients without RSL 
(p < 0.001, p = 0.019, p < 0.001, p = 0.003, respectively). No 
effect of gender on RSL existence was observed (p > 0.05). 
Distribution of the age, abdominal visceral fat, abdominal 
subcutaneous fat, and total fat is shown in Table 2. In cas-
es with low HDL cholesterol level, high LDL cholesterol 
Figure 2. Computed tomography showing cross-sectional abdominal areas 
at umbilicus level in a patient demonstrating fat distribution
Table 1. Distribution of the risk factors
Parameter n %
Gender (M/F) 30/42 41.7/58.3
RSL 35 48.6
HDL (low) 29 40.3
LDL (high) 19 26.4
VLDL (high) 18 25.0
Triglyceride (high) 23 31.9
Total cholesterol (high) 35 48.6




M – male, F – female, HDL – high-density lipoprotein, LDL – low-density lipoprotein, 
VLDL – very low-density lipoprotein, MS – metabolic syndrome, DM – diabetes mellitus, 
HT – hypertension
Table 2. Age, visceral fat, subcutaneous fat, and total fat distribution
Parameter Mean ± SD Min-Max
Age 58.43 ± 15.61 28.00-89.00
Visceral fat (m2) 302.35 ± 481.44 21.61-2944.88
Subcutaneous fat (m2) 257.38 ± 104.79 20.47-483.50
Total fat (m2) 559.72 ± 519.82 55.46-3277.48
Table 3. Relation between risk factors and renal sinus lipomatosis
Parameter RSL (+) RSL (–) p
Mean ± SD Mean ± SD
Age 65.46 ± 11.32 51.78 ± 16.32 < 0.001**a
Visceral fat 442.32 ± 628.96 169.94 ± 2155.00 0.019*a
Subcutaneous fat 302.82 ± 89.83 214.39 ± 100.63 < 0.001**a
Total fat 745.14 ± 645.41 384.33 ± 272.86 0.003**a
Gender, n (%)
Male 15 (50) 15 (50) 0.842b
Female 20 (47.6) 22 (52.4)
HDL, n (%)
Normal 13 (30.2) 30 (69.8) < 0.001**b
Low 22 (75.9) 7 (24.1)
LDL, n (%)
Normal 18 (34) 35 (66) < 0.001**b
High 17 (89.5) 2 (10.5)
VLDL, n (%)
Normal 18 (33.3) 36 (66.7) < 0.001**b
High 17 (94.4) 1 (5.6)
Triglyceride, n (%)
Normal 14 (28.6) 35 (71.4) < 0.001**b
High 21 (91.3) 2 (8.7)
Total cholesterol, n (%)
Normal 8 (21.6) 29 (78.4) < 0.001**b
High 27 (77.1) 8 (22.9)
Glucose, n (%)
Normal 3 (9.4) 29 (90.6) < 0.001**b
High 32 (80) 8 (20)
MS, n (%)
No 7 (17.9) 32 (82.1) < 0.001**b
Yes 28 (84.8) 5 (15.2)
DM, n (%)
No 17 (32.7) 35 (67.3) < 0.001**b
Yes 18 (90) 2 (10)
HT, n (%)
No 12 (33.3) 24 (66.7) 0.009**b
Yes 23 (63.9) 13 (36.1)
aIndependent samples t test, bPearson c2 test, *p < 0.05, **p < 0.01, RSL – renal sinus lipoma-
tosis, HDL – high-density lipoprotein, LDL – low-density lipoprotein, VLDL – very low-density 
lipoprotein, MS – metabolic syndrome, DM – diabetes mellitus, HT – hypertension
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from simple lipomatosis [13]. Furthermore, RSL does not 
manifest a marked atrophy, destruction, or accompany-
ing stone in the kidney. Renal sinus lipomatosis is rapidly 
visible through ultrasound, CT, and MR examinations of 
the kidney. Computed tomography and MRI can show 
fatty components that are directly involved in RSL [14]. 
However, CT is superior to MRI in identifying fat tissue 
with low attenuation values. Proliferation of fatty tissue (s) 
in the renal sinus can be clearly assessed on CT scan [3].
MS includes a number of metabolic parameters that 
are related to increased cardiovascular risks [15]. Meta-
bolic risk factors include visceral obesity, high blood pres-
sure, high blood glucose level, and high blood triglyceride 
level. Treatments for HT, T2 DM, and hypertriglyceridae-
mia are also included [16].
A few studies have reported the relationship between 
renal sinus fat volume, cardiovascular risk factors, and 
visceral adipose tissue volume [6,7]. Murakami et al. [6] 
argued that renal sinus fat volume correlated moderately 
with visceral fat volume. They showed a poor correlation 
between renal sinus fat volume and HDL cholesterol and 
HT. Chughtai et al. [7] found a relationship between renal 
sinus fat volume, the number of prescribed antihyperten-
sive medications, and stage II hypertension. However, no 
study in the literature investigated the relationship between 
RSL, metabolic risk factors, abdominal visceral fat, and ab-
dominal subcutaneous fat.
In the present study, we found that low levels of HDL 
cholesterol, and high levels of LDL cholesterol, VLDL cho-
lesterol, triglyceride, total cholesterol, and glucose were 
statistically significantly higher in patients with RSL. In the 
presence of MS, T2 DM, and HT, the levels of RSL were 
statistically significantly higher. Age, abdominal visceral fat, 
abdominal subcutaneous fat, and total abdominal fat were 
at statistically significantly higher levels in RSL-present pa-
tients than in RSL-absent patients. In the logistic regression 
analysis, however, we found that only age, high total choles-
terol level, high glucose level, and abdominal subcutaneous 
fat were associated with the presence of RSL.
There are some limitations to our study. First, we 
could not evaluate the relation between waist circumfer-
ence and RSL presence because our study was retrospec-
tive. Second, the small sample size of the study may have 
had a limiting effect on our findings. 
Table 4. Results of logistic regression analysis
Parameter β p Odds ratio 95% CI for odds ratio
Lower Upper
Age 0.069 0.048* 1.072 1.001 1.148
Cholesterol 2.226 0.017* 9.261 1.477 58.070
Glucose 3.532 0.001** 34.197 4.167 280.658
Subcutaneous fat 0.016 0.002** 1.017 1.006 1.027
Constant –8.909 0.002** 0.000 – –
level, high VLDL cholesterol level, high triglyceride level, 
high total cholesterol level, and high glucose level, RSL 
existence was observed at statistically significantly higher 
levels (p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001, 
p < 0.001, respectively). In the presence of MS, DM, and 
HT, the presence of RSL, statistically, was observed to be at 
a significantly higher level (p < 0.001, p < 0.001, p = 0.009, 
respectively) (p < 0.001, p < 0.001, p = 0.009, respective-
ly). The relation between risk factors and RSL is shown in 
Table 3. A logistic regression analysis was performed to ex-
amine the factors affecting RSL presence together. It was 
observed that the model formed as a result of the evalua-
tion using the backward method proved to be statistically 
significant (c2 = 63.102, p < 0.001). While the model’s rate 
of accuracy in estimating RSL – present cases was 91.4%, 
the rate of accuracy in estimating cases without RSL 
(the specificity) was 89.2%. The overall accuracy was 90.3%. 
It was observed that age, high total cholesterol level, high 
glucose level, and abdominal subcutaneous fat variables 
were included in the obtained model. According to the 
findings, a unit increase in age value increased the prob-
ability of occurrence of RSL by 1.072-fold (OR [95% CI]: 
1.072 [1.001, 1.148], p = 0.048). The likelihood of RSL in 
the presence of high total cholesterol level was 9.261 times 
higher than in the absence of high total cholesterol level 
(OR [95% CI]: 9.261 [1.477, 58.070], p = 0.017). The prob-
ability of RSL in cases with high glucose level was observed 
to be 34.197 times higher when compared to the cases 
without high glucose level (OR [95% CI]: 34.197 [4.167, 
280.658], p = 0.001). It was shown that an increase of a sin-
gle unit of abdominal subcutaneous fat value increased 
the likelihood of the occurrence of RSL by 1.017-fold (OR 
[95% CI]: 1.017 [1.006, 1.027], p = 0.002). The results of 
logistic regression analysis are shown in Table 4.
Discussion
Renal sinus lipomatosis was first reported in the medical 
literature by Peacock and Balle [11]. Although the cause 
has not been fully explained, it can be seen in cases such 
as progressive age, obesity, Cushing’s disease, and steroid 
use [12]. In contrast to renal replacement lipomatosis, 
the mass effect caused by RSL rarely causes clinical symp-
toms, because renal caliceal obstruction does not result 
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Conclusions
In conclusion, this is the first study to evaluate the 
relationship between RSL and metabolic risk factors, ab-
dominal visceral fat and abdominal subcutaneous fat. Our 
findings demonstrate an association between the presence 
of RSL and age, high total cholesterol level, high glucose 
level, and abdominal subcutaneous fat. These findings 
suggest that radiologists should show due care about 
RSL presence when reporting USG, CT, and MRI exam-
inations, and that they should give place to RSL in their 
reports when they detect it in radiological examinations. 
The findings also suggest that clinicians should be on full 
alert for the relationship between RSL and metabolic fac-
tors in cases where RSL is detected. However, we think 
large-N studies are needed to more accurately explain the 
relationship between RSL and abdominal subcutaneous 
fat, abdominal visceral fat, and metabolic factors.
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